Literature DB >> 24391774

Glutathione S-transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: an evidence-based meta-analysis.

Shuai Zhen1, Chen-Ming Hu2, Li-Hong Bian2.   

Abstract

BACKGROUND: Human papillomavirus (HPV) infection is considered the major cause of cervical cancer (CC), but a number of infected women do not develop invasive lesions, suggesting the role of genetic susceptibility and environmental co-factors for cancer outbreak. Glutathione S- transferases (GSTs) are multifunctional enzymes that play a key role in the detoxification of varieties of both endogenous products of oxidative stress and exogenous carcinogens.
METHODS: MEDLINE, EMBASE, and Cochrane databases were searched. All studies evaluating the association between GSTM1 polymorphisms and cervical cancer were included. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using fixed-or random-effects model.
RESULTS: A total of 23 case-control studies were included in the meta-analysis. The overall result showed that the association between GSTM1 null genotype and risk for cervical cancer was statistically significant (OR = 1.56; 95%CI, 1.39-1.75). Subgroup analyses were performed based on ethnicity, smoking and HPV infection. Our results showed that smokers with null GSTM1 genotype had higher risk of cervical cancer (OR = 2.27, 95%CI, 1.46-3.54). For the ethnicity stratification, significant increased risk of null GSTM1 genotype was found in Chinese and Indian population, but no increased risk in other population was found.
CONCLUSIONS: this meta-analysis provided strong evidence that the GSTM1 genotype is associated with CC development, especially in Chinese and Indian populations. Smoking and HPV infection modified the association between the null GSTM1 genotype and CC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24391774      PMCID: PMC3877062          DOI: 10.1371/journal.pone.0083497

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Cervical cancer (CC) is the second most common gynecologic malignancy in the world and the seventh most frequent overall malignancy [1]. Generally, more than 85% of the global burden occurs in developing countries, where CC accounts for 15% of all female cancers. High-risk regions include Eastern and Western Africa, Southern Africa, South America, and Middle Africa. The incidence rates are the lowest in Western Asia and Northern America. The different incidence rates in different areas indicate that genetic and environmental factors play roles in CC development. According to several epidemiological and biological studies, human papilloma virus (HPV) infection is the dominant etiological event in CC development; however, it is insufficient as a causal agent because this virus is also detected at a certain frequency among women who are cytologically normal, and CC occurs in only a fraction of HPV-infected women. Additional features of the host, including an active sexual history, weakened immune function, and cigarette smoking, have been confirmed as risk factors for CC [2]. Among these factors, smoking is associated with a significantly increased risk, and its effects, which are enhanced by interaction with HPV infection [3] but appear to be independent of socioeconomic status and sexual behavior [4], are dose-dependent [3]. In fact, cigarette smoke carcinogens, polycyclic aromatic hydrocarbons (PAHs), and benzo(α)pyrene have been detected in the cervical mucus of smokers, while cigarette smoke carcinogen-specific DNA adducts (e.g. NNK) have been found in the cervical epithelial cells of cigarette smokers [5]. These results suggest that tobacco smoking could increase the risk of tumor onset and viral infection persistence. Therefore, molecular studies have identified polymorphic gene products that are associated with tobacco smoke procarcinogen metabolism and thus might determine the individual predisposition to CC. Previous studies have shown that genetic variations in the glutathione S-transferases (GSTs) affect human phase II detoxification enzymes involved in the detoxification of various exogenous and endogenous reactive species [6]. Cytosolic GSTs play a role in the conjugation of glutathione to the products of endogenous lipid peroxidation and detoxification of tobacco smoke-associated carcinogenic aflatoxin electrophiles and PAHs. The mode of action of GSTs is thought to involve simultaneous enzyme activation and detoxification and GSTs could affect the modulation of reactive species that form DNA adducts and cause somatic mutations [7]. Accordingly, several studies have identified an association between genetic polymorphisms of GSTs and the risk of cancer development. GSTM1 facilitates the excretion of a wide range of carcinogens, reactive oxygen species, and chemotherapeutic agents with a variety of substrate specificities. Its allelic variant *0 (null allele) caus7es a completely lack of enzymatic activity to bind genotoxic substrates such as epoxides derived from aflatoxin and PAHs [8]. Many epidemiological studies have evaluated GSTM1 and the risk of CC in different populations; however, the results have been inconsistent [9], [10]. Although a few meta-analyses regarding gene polymorphisms and CC have been performed, to our knowledge, no gene–environment interactions have been explored, especially regarding HPV. We wanted to investigate whether some GST polymorphisms could influence the risk of CC development in a cohort of HPV-infected women, either alone or in combination with a smoking habit. Therefore, we conducted a meta-analysis regarding the effect of GSTM1 gene polymorphisms on the CC risk and explored the gene–environment interaction with regard to CC risk.

Materials and Methods

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [11]. A pre-specified protocol that included the data sources, search strategy, inclusion/exclusion criteria for the articles, and analysis methods was developed before the beginning of this study.

Selection criteria and search strategy

We followed the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) [12]. A systematic search was conducted by the authors (Z.S. and H.C.M). The identification of relevant studies was conducted in a search of the Cochrane Databases, PubMed, Medline, and EMBASE up to June 2013, using the following terms without any restriction on language. The search terms were “cervical cancer”, “cervical tumor”, “cervical neoplasm”, “cervical adenocarcinoma”, “uterine cervix cancer”, “CC”, “glutathione-S-transferase”, “GST”, “GSTM”, “polymorphism”, “polymorphisms”, and “variant”. The PubMed search strategy is shown in (Figure 1). The references of all eligible articles were checked for other relevant articles.
Figure 1

PUBMED search strategy.

Inclusion/exclusion criteria

The inclusion criteria were as follows: case-control studies that investigated the association between GSTM1 polymorphisms and the risk of CC and studies that presented original data and the numbers of null GSTM1 genotypes among the cases and controls. Exclusion criteria included the following: duplicate publications; case reports; insufficient data to construct a 2×2 table of the test result; precancerous lesions included among the cases; lack of a control group; and abstracts, reviews, talks, and review class documentations.

Data extraction and quality assessment

The data extracted from each study included the authors, publication year, country of origin, average ages of cases and controls, number of null GSTM1 genotypes among the cases and controls, and the adjusted ORs of the selected studies. Smokers were defined as those with a lifetime history of smoking more than 100 cigarettes and who had smoked continuously for at least 1 year until the time of diagnosis; non-smokers were defined as those who had never smoked. The 2×2 tables were reconstructed. Two (Z.S. and H.C.M.) authors independently assessed the articles according to the inclusion/exclusion criteria and referred to Corresponding Author (B.L.H.) in cases of disagreement. When important data were not provided, the authors contacted the article authors via e-mail. The study quality was assessed according to the revised tool for the quality assessment of diagnostic accuracy studies (QUADAS-2; a description is shown in Table 1) [13] and the standards for reporting diagnostic accuracy (STARD) tool [14]. Each item was scored as a “yes”, “no”, or “unclear” if there was insufficient information to make an accurate judgment.
Table 1

QUADAS List.

Item No.Description
1Representative patient spectrum
2Clear description of selection criteria
3Acceptable reference standard
4Acceptable delay between tests
5Avoiding partial verification bias
6Sufficient differential verification bias
7Avoiding incorporation bias
8Sufficient description of index test
9Sufficient description of reference test
10Blinded interpretation of index test results
11Blinded interpretation of index reference results
12Availability of clinical data to the researchers
13Reporting of uninterpretable indeterminate results
14Explanation of withdrawals from study

Statistical analysis

Data analysis was performed using Review Manager (version 5.0) and STATA software (version 11, StataCorp LP, College Station, TX, USA).The association between the GSTM1 gene polymorphisms and CC was estimated by calculating the pooled odds ratios (ORs) with 95% confidence intervals (CIs). ORs were used to analyze the results, and their corresponding 95% CIs were estimated. Cross-study heterogeneity was estimated using the I2-statistic and Q-statistic [15]. The meta-analysis was conducted using the random-effects or fixed effects methods model, based on the pooled effect estimates in the presence (p<0.1 and I2>50%) or absence (p>0.1 and I2<50%) of heterogeneity [16]. An evaluation of the potential publication bias was estimated by constructing funnel plots for visual inspection and Egger's regression asymmetry test [17]. Studies were categorized into subgroups based on ethnicity, HPV infection, and smoking status.

Results

Characteristics and quality assessment of the included studies

A flow diagram of the study selection process is shown in Figure 2. The literature search identified 171 potentially relevant studies; of these, 91 were excluded after screening the titles and abstracts. The full-text studies were retrieved for a detailed assessment. Fifty-seven were excluded for various reasons (26 studies did not involve CC, 18did not involve polymorphisms, 5 did not include controls, 4 were conducted on overlapping populations, and 4 were review articles). Finally, 23 case-control studies [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40] were included in the GSTM1 genotype meta-analysis (2343 cases and 2662 controls). The meta-analysis included studies from China, India, Japan, Korea, Italy, USA, Greece, Brazil, Turkey, and Thailand. The characteristics of studies included in the meta-analysis are presented in Table 2. The results of the QUADAS-2 assessment of the included studies are shown in Figure 3.
Figure 2

Flow diagram of study selection.

Table 2

Characteristics of studies included in the meta-analysis.

StudyYearEthnicityStudy designMean age of casesMean age of controlsCases/ControlsNull GSTM1 genotype Cases/Controls
Agodi [18] 2010ItalyHospitalNANA27/16215/17
Agorastos [19] 2007GreeceHospitalNANA176/11433/60
de Carvalho [20] 2008BrazilHospitalNANA43/8628/49
Goodman [21] 2001AmericaPopulation32.339.1131/18074/98
Huang [22] 2006ChinaHospital40.841.247/7830/32
Joseph [23] 2006IndiaPopulation4647147/16579/54
Kim [24] 2000KoreaPopulation46.546.5181/18195/96
Kiran B [25] 2010TurkeyHospitalNANA46/5215/16
Lee [26] 2004KoreaHospitalNANA81/8642/42
Liu [27] 2009ChinaHospitalNANA62/4540/13
Ma [28] 2009ChinaHospital46.748.843/4529/15
Nishino [29] 2008JapanPopulation41.640.6124/12577/59
Niwa [30] 2005JapanHospital47.256.2131/32070/184
Palma [31] 2010ItalyHospitalNANA81/11149/58
Seltheetham-Ishida [32] 2009ThailandPopulationNANA69/7254/56
Sharma [33] 2004IndiaHospitalNANA142/9681/33
Sierra-Torres [34] 2003AmericaPopulation38.334.869/7235/29
Sierra-Torres [35] 2006AmericaPopulation45.542.391/9236/38
Singh [36] 2008IndiaPopulation45.250.3150/16864/40
Sobti [37] 2006IndiaHospital48.648103/10342/38
Song [38] 2006ChinaHospital49.147.2130/13077/57
Ueda [39] 2008JapanPopulationNANA144/5475/28
Zhou [40] 2006ChinaHospital40.750.5125/12573/54
Figure 3

Graphical display of study characteristics according to QUADAS II recommendations.

(Left: Proportion of studies with low, or high, or unclear concerns regarding applicability; Right: Proportion of studies with low, high or unclear risk of bias.).

Graphical display of study characteristics according to QUADAS II recommendations.

(Left: Proportion of studies with low, or high, or unclear concerns regarding applicability; Right: Proportion of studies with low, high or unclear risk of bias.).

Data synthesis and meta-analysis

The forest plot of the GSTM1 meta-analysis is shown in Figure 4. Heterogeneity was observed in the GSTM1 studies (p<0.001, I2 = 67% for GSTM1), and therefore, a random-effects model was used. The overall result showed that the GSTM1 null allele was related to an increased risk of CC (OR = 1.56; 95%CI, 1.39–1.75).
Figure 4

Forest Plot for the Overall Association Between GSTM1 Gene Polymorphism and Cervical Cancer Risk.

Subgroup analyses were performed according to smoking history, ethnicity, and HPV infection status. The results showed that smokers had an increased risk of CC (OR = 2.27; 95%CI, 1.46–3.54), while no significant increased risk was observed in non-smokers (Figure 5). After stratification, the heterogeneity decreased significantly (P = 0.229, I2 = 28.9% for non-smokers and P = 0.734, I2 = 0% for smokers). In the ethnicity stratification, a moderately significant increase in risk was associated with the null GSTM1 genotype in Chinese (OR = 2.51; 95%CI, 1.73–3.65) and Indian populations (OR = 2.07; 95%CI, 1.49–2.88), but the risk observed in other populations was not significant (Figure 6). In the HPV infection status stratification, the results showed that HPV infection was associated with the risk of CC (OR = 22.51; 95%CI, 16.27–31.15; I2 = 61.8%, P = 0.023; Figure 7).
Figure 5

Relationship Between GSTM1 Gene Polymorphism and Cervical Cancer Risk by Smoking Status.

Figure 6

Relationship Between GSTM1 Gene Polymorphism and Cervical Cancer Risk by Ethnicity.

Figure 7

Relationship Between GSTM1 Gene Polymorphism and Cervical Cancer Risk by HPV infection.

Heterogeneity assessment

Significant cross-study heterogeneity was present in both the overall and subgroup analyses. We explored several possible sources of this cross-study heterogeneity, such as ethnicity, the DNA genotyping sample source, sample size, and quality score. However, none of these variables could explain the heterogeneity, which could have been caused by the limited number of included studies. Regardless of the p value, ethnicity and study design were thought to play important roles. Next, we filtered 3 studies (American population and study design are population-based) and obtained an I2of 0%. Further studies are needed to confirm the roles of ethnicity and study design with regard to heterogeneity.

Discussion

Despite CC being among the most common cancers worldwide, the etiology is not yet clearly understood. The present and related studies show that the GST-null genotype is associated with an increased cancer incidence. Moreover, GSTs also play an important modulatory role in the induction of other enzymes and proteins involved in cellular functions such as DNA repair [41]. The relationship between GST gene polymorphisms and CC has been investigated in various studies. However, the association between these variables has been controversial, and discrepancies could have been due to limited sample numbers and ethnic differences. Our meta-analysis showed a possible role for GSTM1 polymorphism, which interacts with smoking status and HPV infection status, in the promotion of CC development; also the risk of CC was statistically significant in Chinese and Indian populations, but not in other population, indicating that these differences in cancer susceptibility varied according to ethnicity. Additionally, the data showed that the frequency of the GSTM1 null allele genotype was higher in American and Japanese populations than in Chinese and Indian populations, suggesting that the varied effects of the genotype might be attributable to differences in lifestyle, nutrition, environmental factors, and genetic factors. Cigarette smoking, which decreases the ability to clear oncogenic infections, has been found to be an independent risk factor of CC [42]. Jee et al. [43] reported that ever smokers with the GSTP1 A/A (variant allele, homozygous) genotype had an increased risk of invasive CC. Because most women in this region rarely smoke, the exposure to smoke is passive; this type of exposure has been found to increase the risk of CC. A significant association was found between CC and passive smoking, but not active smoking [44].Our study showed that tobacco components are modified by metabolic enzymes and can promote malignant cellular growth. The mode of action occurs through the activation and detoxification of tobacco carcinogens; therefore, GST polymorphisms might be expected to affect the risk of cancer development among smokers. The absence of GST activity, which is caused by an inherited deletion of the GST, has been reported to increase the risk of several tobacco-related cancers. We therefore hypothesized that smoking and the GST genotype might synergistically influence CC development. Our study showed that the null GSTM1 genotype might increase the CC risk among smokers, thus providing strong evidence for an association between GSTs and CC risk. In previous decades, a few meta-analyses that investigated the association between GST polymorphisms and CC found that this association is, however, affected by an important limitation [45]. For example, the study failed to perform a subgroup analysis according to major environmental determinations such as the HPV infection status. Our meta-analysis included some limitations. First, heterogeneity was a major problem in this meta-analysis. We explored several possible sources of heterogeneity, including the sample size and DNA source. However, we failed to find a clear reason, indicating that a conservative manner should be adopted when interpreting these results. Second, some control sources were population-based [46], while others were hospital-based; the latter are more prone to bias than are the former. Finally, the sample size reported in the literature is still relatively small and might not provide sufficient power to estimate the association between the null GSTM1 polymorphism and CC risk. In conclusion, this meta-analysis provided strong evidence that the GSTM1 genotype is associated with CC development, especially in Chinese and Indian populations. Smoking and HPV infection modified the association between the null GSTM1 genotype and CC. Studies with large sample sizes should be performed to confirm this finding. Additionally, further studies that investigate the effects of gene–environment interactions on CC risk are required. PRISMA checklist. (PDF) Click here for additional data file. PRISMA Flow Diagram. (PDF) Click here for additional data file.
  38 in total

1.  Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States).

Authors:  Anna R Giuliano; Rebecca L Sedjo; Denise J Roe; Robin Harri; Susie Baldwi; Mary R Papenfuss; Martha Abrahamsen; Paula Inserra
Journal:  Cancer Causes Control       Date:  2002-11       Impact factor: 2.506

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

4.  Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers.

Authors:  B Prokopczyk; J E Cox; D Hoffmann; S E Waggoner
Journal:  J Natl Cancer Inst       Date:  1997-06-18       Impact factor: 13.506

5.  Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in sicily.

Authors:  Antonella Agodi; Martina Barchitta; Rosalba Cipresso; Rubina Marzagalli; Nadia La Rosa; Melania Caruso; Maria Grazia Castiglione; Salvatore Travali
Journal:  Int J Gynecol Cancer       Date:  2010-01       Impact factor: 3.437

6.  GSTP1 polymorphism, cigarette smoking and cervical cancer risk in Korean women.

Authors:  Sun Ha Jee; Jong Eun Lee; Sook Kim; Ji Hyun Kim; Soo Jong Um; Sung Jong Lee; Sung Eun Namkoong; Jong Sup Park
Journal:  Yonsei Med J       Date:  2002-12       Impact factor: 2.759

7.  Glutathione S-transferase (GSTM1 and GSTT1) polymorphisms in cervical cancer in Northeastern Thailand.

Authors:  Wannapa Settheetham-Ishida; Pissamai Yuenyao; Churairat Kularbkaew; Dariwan Settheetham; Takafumi Ishida
Journal:  Asian Pac J Cancer Prev       Date:  2009 Jul-Sep

8.  Interaction between glutathione-S-transferase polymorphisms, smoking habit, and HPV infection in cervical cancer risk.

Authors:  Selena Palma; Flavia Novelli; Luca Padua; Aldo Venuti; Grazia Prignano; Luciano Mariani; Renata Cozzi; Donatella Tirindelli; Antonella Testa
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-13       Impact factor: 4.553

Review 9.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

10.  Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection.

Authors:  L Kjellberg; G Hallmans; A M Ahren; R Johansson; F Bergman; G Wadell; T Angström; J Dillner
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  2 in total

1.  Glutathione S-transferase omega gene polymorphism as a biomarker for human papilloma virus and cervical cancer in Iranian women

Authors:  Sara Zamani; Amir Sohrabi; Marjan Rahnamaye-Farzami; Seyed Masoud Hosseini
Journal:  J Turk Ger Gynecol Assoc       Date:  2018-08-06

2.  Curcumin Nanoformulation for Cervical Cancer Treatment.

Authors:  Mohd S Zaman; Neeraj Chauhan; Murali M Yallapu; Rishi K Gara; Diane M Maher; Sonam Kumari; Mohammed Sikander; Sheema Khan; Nadeem Zafar; Meena Jaggi; Subhash C Chauhan
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.